As an ISCRM postdoctoral fellow, Evelyn Abraham will validate reprogramming of human Müller glia as a treatment for retinal degenerative diseases. She will use patient-derived retinal organoids to model late-stage retinal disease characterized by photoreceptor dysfunction and loss in vitro, and regenerate retinal neurons to assess recovery, gene expression, and circuit integration. Her work will test the feasibility, scalability, and functionality of Müller glia–driven endogenous regeneration in a human disease model, advancing its translational potential.
